Effects of Yiqi Sanju formula on non-alcoholic fatty liver disease: A randomized controlled trial

Journal of Chinese Integrative Medicine

Volumn 6, Issue 8, 2008, Pages 793-798

  Lou, Shao Ying ^a   Liu, Yi ^a   Ma, Yu Ying ^a   Chen, Hai Ying ^a   Chen, Wei Hua ^a   Ying, Jian ^a   He, Yan Ming ^a   Wang, Wen Jian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Fatty liver; Insulin resistence; Ranomized controlled trials; Spiral CT; Yiqi Sanju formula

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; HERBACEOUS AGENT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; YIQI SANJU;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHINESE MEDICINE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; DRUGS, CHINESE HERBAL; FATTY LIVER; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PHYTOTHERAPY; TREATMENT OUTCOME;

EID: 50049133236     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20080805     Document Type: Article

References (12)

1. Fatty Liver and Alcoholic Liver Disease Study Group of Chinese Liver Disease Association. Guidelines for diagnosis and treatment of non-alcoholic fatty liver disease. Gan Zang. 2006; 11(1): 68-70. Chinese.
2. Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med. 2008; 19(2): 75-82.
3. Zheng XY. Guiding principles for clinical research on new drugs of traditional Chinese medicine. Beijing: Chinese Medical Science and Technology Press. 2002: 148. Chinese.
4. Leclercq IA, Da Silva Morais A, Schroyen B, et al. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007; 47(1): 142-156.
5. Wang WJ. Foundation and application of aggregation syndrome theory in traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao. 2007; 5 (2): 111-114. Chinese with abstract in English.
6. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004; 10 (12): 1344-1351.
7. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006; 55(8): 2256-2264.
8. Wang SH, Wang WJ, Wang XF, et al. Effect of Astragalus polysaccharides and berberine on carbohydrate metabolism and cell differentiation in 3T3-L1 adipocytes. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2004; 24 (10): 926-928. Chinese with abstract in English.
9. He CY, Wang WJ, Li F, et al. Clinical research of Yiqi Sanju Formula in treating central obese men at high risk of metabolic syndrome. Zhong Xi Yi Jie He Xue Bao. 2007; 5(3): 263-267. Chinese with abstract in English.
10. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005; 172(7): 899-905.
11. Rodríguez-Leal GA, Morán S, Gallardo I, et al. Assessment of high sensitivity C-reactive protein (hs-CRP) as a marker of liver inflammation in patients with metabolic syndrome. Rev Gastroenterol Mex. 2006; 71 (1): 39-45.
12. Zhou H, Xu B, Xu NN, et al. The comparison of diagnostic value between CT and ultrasonic examination in low-grade fatty liver. Shou Du Yi Ke Da Xue Xue Bao. 2006; 27(4): 541-543. Chinese with abstract in English.